Gleason grading and prognostic factors in carcinoma of the prostate
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerMicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate CancerThe evolving Gleason grading systemDiagnosis of prostate cancer via nanotechnological approachElevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcomeA study to correlate histopathology, biochemical marker and immunohistochemical expression of sex-steroid receptors in prostatic growthEmphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancerMultiscale integration of -omic, imaging, and clinical data in biomedical informatics.Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and bloodMR measurement of luminal water in prostate gland: Quantitative correlation between MRI and histology.Integrative molecular concept modeling of prostate cancer progression.Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer.Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy.Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancerMolecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular networkGenotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate CancerPrognostic factors in prostate cancer.Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia.Prognostic value of discs large homolog 7 transcript levels in prostate cancer.Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cellsCombination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.Constitutive and Inducible Expression of Invasion-related Factors in PC-3 Prostate Cancer Cells.Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancerGene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.Automated prostate tissue referencing for cancer detection and diagnosis.A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.MicroRNA‑361‑5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non‑small cell lung cancerExpression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and CD44+CD24- stemness.Hedgehog signaling in prostate cancer.Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer.Periprostatic adipocytes act as a driving force for prostate cancer progression in obesityThe Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma.Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart centerDiagnosis of adenocarcinoma in prostate needle biopsy tissue.Isolation and analysis of discreet human prostate cellular populations
P2860
Q26738703-99F8E560-035E-4B2C-996D-2339CDAB2B88Q26739708-08298B30-6A28-4F0B-A523-0FEDBE9E3B34Q26751983-BA871AE7-FCDB-4F4C-ABC6-1FF31A7A0FDDQ26752936-4A8040BA-126E-4895-9C23-85AF64B16FA2Q26777322-C6F4C53E-F1C5-4F72-9655-C8F85432F2E4Q28477590-E229CA97-BA03-4BA0-842B-E842B233155BQ28656332-6710CB8E-8F60-41EC-AFD3-78A0B6134BF0Q28709995-F6E3AABF-FA5A-4B88-94FD-29D796050EE3Q30581136-BE0D0C6C-D8F4-4097-9386-F58D31C12C13Q31035031-FDADCCCE-85E7-461B-8E26-F343C92F918DQ31045532-FB6FD9FB-3851-4DD8-A074-79DA8B0A41A1Q31157477-C95405FB-70F9-4FDE-8F8F-44D662415E51Q33266777-6CBBBB61-E273-48C5-9AD5-1C1069425BD7Q33279572-3CDD4DD4-212D-4B9D-8863-81C0CC05C0C9Q33361134-4B513DA1-95D8-4AC4-BF32-2266640B7D15Q33494984-9023B299-9D3A-48A0-904F-7826978543C7Q33566716-0425B1FC-442A-43BB-A521-CE7DEEE90939Q33677773-7F23CB4C-1705-4E73-AFC1-FC3DD0DE2575Q33823048-F4D86CD0-C208-4BE0-A8FC-95707C39346BQ34682069-8B1EDBE6-1AA8-41C5-B285-63B7388A482CQ35040471-8E87BDBA-85B5-4ABE-9973-76E07873A465Q35070576-BE1495C4-C12D-44AB-A315-9A69589A123BQ35312855-7FA72F2B-9722-4A5A-9F11-C3E444A5A669Q35651467-BA11C741-9C38-4F5C-A7B3-800B09404B17Q35820978-B0BF4C00-BDD0-4D41-BF21-8572302164D7Q35919780-C784F3D8-8F6E-4559-9ED1-9865827BB647Q36021088-B1EB1A6F-FD2B-4DC5-8F85-E59B5729E745Q36035875-636CAFF4-8458-41FA-A8D9-5EB6591C16C1Q36186223-E735DF2F-17F1-4D4C-8490-509C3197EF4EQ36224845-E9F251CE-4D8A-43A7-B83C-BD60016155D5Q36290408-4B516931-EE42-43FF-AD01-F0316AC01BF6Q36395223-4DBDC2FC-FDC7-499C-BD3A-CB8A756B76C7Q36429482-D3DB5EB9-5F6C-4109-BB34-D3CE716162BFQ36430872-6F76B88C-7B2F-499A-AC78-1D6D46B8DC9DQ36511320-C4052274-E66D-475F-8F7E-860F084AB9EDQ36568781-16A8FF70-B48D-4FE4-994B-AC1D1975A4C4Q36577621-5AAF9711-7733-4AF8-9174-852D9F88B9BDQ36584318-F3715F04-1DAD-45DA-A47F-2706117B79A7Q36703455-7E5B386E-FC27-4A8A-9A4D-5850582739CAQ36863464-77E709F8-E194-400C-ACD0-D2DC1A5753EB
P2860
Gleason grading and prognostic factors in carcinoma of the prostate
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Gleason grading and prognostic factors in carcinoma of the prostate
@ast
Gleason grading and prognostic factors in carcinoma of the prostate
@en
type
label
Gleason grading and prognostic factors in carcinoma of the prostate
@ast
Gleason grading and prognostic factors in carcinoma of the prostate
@en
prefLabel
Gleason grading and prognostic factors in carcinoma of the prostate
@ast
Gleason grading and prognostic factors in carcinoma of the prostate
@en
P3181
P1433
P1476
Gleason grading and prognostic factors in carcinoma of the prostate
@en
P2093
Peter A Humphrey
P2888
P304
P3181
P356
10.1038/MODPATHOL.3800054
P577
2004-02-13T00:00:00Z
P5875
P6179
1027726502